{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:34:59Z","timestamp":1783042499119,"version":"3.54.6"},"reference-count":18,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cerebrovasc Dis"],"abstract":"<jats:p>Introduction: The optimal intensity of statin therapy after nontraumatic intracerebral hemorrhage (ICH) remains controversial. This study aimed to compare safety and efficacy outcomes between moderate- and high-intensity statin therapy in post-ICH patients using real-world data to inform secondary prevention strategies. Methods: In this retrospective analysis of the TriNetX Global Collaborative Network database (a federated electronic health records platform), patients with nontraumatic ICH who initiated statin therapy \u22657 days post-ICH were identified. Moderate-intensity statin therapy was defined as atorvastatin 10\u201320 mg, simvastatin 20\u201340 mg, rosuvastatin 5\u201310 mg, pravastatin 40\u201380 mg, lovastatin 40 mg, fluvastatin 40\u201380 mg, or pitavastatin 2\u20134 mg. High-intensity therapy included atorvastatin 40\u201380 mg or rosuvastatin 20\u201340 mg. Primary outcomes included recurrent ICH, ischemic stroke, composite vascular events, and all-cause mortality. Safety outcomes included rhabdomyolysis and hepatic injury. Results: After matching, 8,925 patient pairs were well balanced on baseline demographics and comorbidities. Mean follow-up was 283 days (median 365 days) in both groups. Compared with high-intensity statins, moderate-intensity therapy was associated with lower risks of recurrent ICH (23.4% vs. 24.9%; hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.86\u20130.97; p = 0.002), ischemic stroke (7.1% vs. 10.2%; HR, 0.68; 95% CI, 0.59\u20130.78; p &lt; 0.001), composite vascular events (15.1% vs. 19.5%; HR, 0.74; 95% CI, 0.66\u20130.82; p &lt; 0.001), and all-cause mortality (9.0% vs. 10.2%; HR, 0.87; 95% CI, 0.79\u20130.96; p = 0.004). Rates of rhabdomyolysis (0.3% vs. 0.4%) and hepatic injury (0.5% vs. 0.4%) were low and not significantly different between groups. Conclusion: In this large, real-world analysis, moderate-intensity statins demonstrated statistically significant but modest reductions in recurrent ICH, ischemic stroke, composite vascular events, and all-cause mortality compared with high-intensity statins, without increased adverse events. These findings may support preferential use of moderate-intensity statin therapy in selected post-ICH patients pending confirmation from randomized trials. While these observational findings suggest potential benefits of moderate-intensity statin therapy in selected post-ICH patients, confirmation from randomized controlled trials is needed before definitive clinical recommendations can be made.<\/jats:p>","DOI":"10.1159\/000548628","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:03:48Z","timestamp":1759421028000},"page":"571-578","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Moderate- vs. High-Intensity Statin Therapy after Nontraumatic Intracerebral Hemorrhage: A Real-World Evidence Analysis"],"prefix":"10.1159","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-9266","authenticated-orcid":false,"given":"Majd","family":"Abualrob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1032343"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-02008-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101342"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.11.011"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008627"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01377-1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14421"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeac038"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.035846"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0213-8"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241239523"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics7020038"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.487"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000032466.44170.44"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020214"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34215"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105655"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"}],"container-title":["Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:30:05Z","timestamp":1783009805000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,6,24]]}},"URL":"https:\/\/doi.org\/10.1159\/000548628","archive":["Portico"],"relation":{},"ISSN":["1015-9770","1421-9786"],"issn-type":[{"value":"1015-9770","type":"print"},{"value":"1421-9786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}